Key Updates From the CELESTIAL Trial Presented at ASH 2024

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome resistance.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.

The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.